相关实验视频

Updated: May 26, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

胆道癌中的HER2通路:当前理解和未来方向的快照

Silvia Camera¹, Federico Rossari^1,2, Silvia Foti¹

¹Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.

Targeted oncology

|February 22, 2025

概括

向疗法,特别是HER2抑制剂,对胆道癌 (BTCs) 显示出希望. 研究正在探索它们在这些侵袭性恶性瘤的各种治疗线的有效性.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
分子生物学分子生物学

背景情况:

胆道癌 (BTC) 是一种具有有限治疗选择和不良预后的侵袭性恶性瘤.
最近的进展包括组合化疗和免疫疗法作为转移性BTCs的第一线治疗.
了解分子变化引入了向疗法,扩大了治疗策略超出标准方案.

研究的目的:

审查目前的证据和HER2-改变的胆道癌症的未来方向.
在大约15-20%的BTC病例中,突出显示HER2作为治疗点.
总结HER2抑制剂在高级BTC中的疗效和安全性.

主要方法:

在BTC中对HER2向治疗的研究进行了全面的文献综述.
分析临床试验数据和关于HER2抑制剂的已发表研究.
综合关于疗效,安全性和患者群体的证据.

主要成果:

在15-20%的BTC中注意到HER2的过度表达,特别是胆囊和肝外胆管癌.
HER2 抑制剂在二线和超越的环境中表现出令人鼓舞的疗效和安全性.
目前正在进行的试验正在调查BTC的第一线治疗中的向疗法.

结论:

针对HER2的治疗代表了HER2改变的BTCs治疗的重大进步.
进一步的研究和临床试验对于优化HER2抑制剂在BTC治疗中的使用至关重要.
包括HER2抑制剂在内的向疗法正在扩大胆道癌症的治疗武器库.

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...